1 day ago · Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI inhibitor that originated at Novartis, being developed to prevent stroke and systemic embolism in patients with atrial fibrillation as well as to prevent the ...

1 day ago · Blackstone Life Sciences announced that Novartis will acquire Anthos Therapeutics for up to $3.1 billion.The deal includes a $925 million upfront payment, with additional payments tied to regulatory and commercial milestones. The transaction is expected to close in first half of 2025. Anthos, founded by Blackstone and Novartis in 2019, is developing abelacimab, a novel …

1 day ago · Blackstone Life Sciences And Anthos Therapeutics Announce Agreement For Anthos To Be Acquired By Novartis For Up To $3.1 Billion 01:26am: RE Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront 01:15am

Feb 27, 2019 · Cambridge, Massachusetts, February 27, 2019 – Blackstone Life Sciences today announced the launch of Anthos Therapeutics Inc. (“Anthos”), a new biopharmaceutical company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients.

Aug 15, 2024 · Anthos Therapeutics’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation

CAMBRIDGE, Mass., Nov. 16, 2024–Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiovascular metabolic diseases, presented new data today at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study that ...

Nov 28, 2023 · Anthos Therapeutics was founded by Blackstone Life Sciences in 2019 and obtained from Novartis Pharma AG the exclusive global rights to develop, manufacture, and commercialize abelacimab, a promising novel therapy being developed for patients at …

1 day ago · Anthos est le fruit d'une collaboration lancée en 2019 entre Novartis et Blackstone Life Science, destinées à faire progresser le développement de l'abélacimab à travers les différentes ...

Feb 28, 2019 · Novartis and private investment platform Blackstone Life Sciences have launched a new biopharmaceutical company Anthos Therapeutics focused on targeted therapies for cardiovascular diseases. Based in the US, the new company will develop and commercialise genetically and pharmacologically validated treatments for high-risk cardiovascular patients.

Blackstone Life Sciences announced the launch of Anthos Therapeutics Inc. , a new biopharmaceutical company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients.